Kiora Pharmaceuticals, Inc.
3 clinical trials · 3 recruiting · INDUSTRY
Trials by Kiora Pharmaceuticals, Inc.
RECRUITINGPhase 2NCT06825702
Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema
This is a multi-center, open label study to assess the safety, tolerability, and efficacy of KIO-104 administered by IVT injection to the study eye of eligible participants with...
Sponsor: Kiora Pharmaceuticals, Inc.Enrolling: 284 locations
Macular Edema
RECRUITINGPhase 2NCT06628947
A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
The goal of the study is to investigate the safety, tolerability and efficacy of up to 3 doses of KIO-301 administered by intravitreal (IVT) injection bilaterally every 6 weeks in...
Sponsor: Kiora Pharmaceuticals, Inc.Enrolling: 365 locations
Retinitis Pigmentosa
RECRUITINGPhase 1 / Phase 2NCT05282953
A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to...
A phase I/II dose-escalating study of the safety, tolerability and efficacy of KIO-301 administered intravitreally to patients with retinitis pigmentosa and choroideremia (ABACUS).
Sponsor: Kiora Pharmaceuticals, Inc.Enrolling: 483 locations
Retinitis PigmentosaChoroideremiaNon-Syndromic Rod-Dominant Inherited Retinal Diseases